[1] Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012;54:121-128. DOI: 10.1093/cid/cir745.
[2] Li Z, Liu Y, Chong Y, et al. Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study. Mycoses. 2019;62. DOI: 10.1111/myc.12944.
[3] Ssebambulidde K, Bangdiwala AS, Kwizera R, et al. Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis. Clin Infect Dis 2019; 68:2094-2098. DOI: 10.1093/cid/ciy817.
[4] Wu X, Shen Y. Management of human immunodeficiency virus-associated cryptococcal meningitis: Current status and future directions. Mycoses.2019;62. DOI: 10.1111/myc.12977.
[5] Musubire AK, Meya DB, Rhein J, et al. Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality. PLoS One 2018;13: e0209337. DOI: 10.1371/journal.pone.0209337.
[6] Kashef Hamadani BH, Franco-Paredes C, Mccollister B. Cryptococcosis and cryptococcal meningitis: New predictors and clinical outcomes at a United States academic medical centre. Mycoses 2018;61:314-320. DOI: 10.1111/myc.12742.
[7] Abd El-Wahab EW, Farrag T, and Metwally M. A clinical rule for the prediction of meningitis in HIV patients in the era of combination antiretroviral therapy. Trans R Soc Trop Med Hyg 2020;114: 264-275. DOI: 10.1093/trstmh/trz107.
[8] Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014;58:736-745. DOI: 10.1093/cid/cit794.
[9] Pastick KA, Bangdiwala AS, Abassi M, et al. Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. Open Forum Infect Dis 2019;6:ofz478. DOI: 10.1093/ofid/ofz478.
[10] Tsai WC, Lien CY, Lee JJ, et al. The clinical characteristics of adult cryptococcal meningitis patients who died within one year of treatment with a focus on those with early mortality. J Clin Neurosci 2019;67:80-84. DOI: 10.1016/j.jocn.2019.06.015.
[11] Tenforde MW, Gertz AM, Lawrence DS, et al. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc 2020;23: e25416. DOI: 10.1002/jia2.25416.
[12] Lofgren S, Abassi M, Rhein J, et al. Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. Expert Rev Anti Infect Ther 2017;15: 331-340. DOI: 10.1080/14787210.2017.1285697.
[13]World Health Organization. Consolidated Guidelines on HIV Testing Services: 5Cs: Consent, Confidentiality, Counselling, Correct Results and Connection 2015. https://doi.org/10.13140/RG.2.1.22 63.6882; 2015, Accessed date: 14 April 2020.
[14] Xu L, Tao R, Wu J, et al. Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole. Front Microbiol 2019;10: 2082. DOI: 10.3389/fmicb.2019.02082.
[15] Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. Journal of Clinical Microbiology 2019; 57:e01238-18. DOI: 10.1128/JCM.01238-18.
[16] Luo M, Yang Y, Xu J, et al. A new scoring model for the prediction of mortality in patients with acute kidney injury. Sci Rep 2017;7:7862. DOI: 10.1038/s41598-017-08440-w.
[17] Williamson PR. The relentless march of cryptococcal meningitis. The Lancet Infectious Diseases 2017;17:790-791. DOI: 10.1016/S1473-3099(17)30245-1.
[18] Lessells R J, Mutevedzi P C, Heller T, et al. Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S Afr Med J 2011;101:251-252. DOI: 10.7196/samj.4378.
[19] Kendi C, Penner J, Koech J, et al. Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgraduate Medical Journal 2013;89:73-77. DOI: 10.1136/postgradmedj-2012-130823.
[20] Estelle P, John K, and Pierre DB. Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review. Clin Infect Dis 2017;66: 1122-1132. DOI: 10.1093/cid/cix870.
[21] Anekthananon T, Manosuthi W, Chetchotisakd P, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS 2011;22:665-670. DOI: 10.1258/ijsa.2011.010538.
[22] Carlson RD, Rolfes MA, Birkenkamp KE, et al. Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis 2014;29: 269-279. DOI: 10.1007/s11011-013-9476-1.
[23] Xu L, Zhang X, Guo Y, et al. Unique clinical features of cryptococcal meningitis among Chinese patients without predisposing diseases against patients with predisposing diseases. Med Mycol 2019;57:944-953. DOI: 10.1093/mmy/myy154.
[24] Wu L, Xiao J, Song Y, Gao G, Zhao H. The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study. BMC Infect Dis. 2020 Dec 1;20(1):912. DOI: 10.1186/s12879-020-05661-9.
[25] Hakyemez IN, Erdem H, Beraud G, Lurdes M, et al. Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study. Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1231-1240. DOI: 10.1007/s10096-017-3142-1.
[26] Song W, Shen YZ, Wang ZY, et al. Clinical features and treatment outcomes of human immunodeficiency virus-associated cryptococcal meningitis: a 2-year retrospective analysis. Chin Med J (Engl). 2020 Dec 5;133(23):2787-2795. DOI: 10.1097/CM9.0000000000001191.
[27] Qu J, Zhou T, Zhong C, Deng R, Lü X. Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study. BMC Infect Dis. 2017 Jan 10;17(1):51. doi: 10.1186/s12879-016-2126-6. DOI: 10.1186/s12879-016-2126-6.
[28] Chang CC, Perfect JR. Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity? Curr Opin Infect Dis. 2016 Dec;29(6):539-545. DOI: 10.1097/QCO.0000000000000315.
[29] van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997 Jul 3;337(1):15-21. DOI: 10.1056/NEJM199707033370103.
[30] Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000 Jan;30(1):47-54. DOI: 10.1086/313603.
[31] de Vedia L, Arechavala A, Calderón MI, et al. Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS. Infection. 2013 Dec;41(6):1073-7. DOI: 10.1007/s15010-013-0538-4.
[32] Srichatrapimuk S, Sungkanuparph S. Integrated therapy for HIV and cryptococcosis. AIDS Res Ther. 2016 Nov 29;13(1):42. DOI: 10.1186/s12981-016-0126-7.
[33] Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb 1;50(3):291-322. DOI: 10.1086/649858.
[34] Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis. 2005 Feb 1;40(3):480-2. doi: 10.1086/427222. Epub 2005 Jan 10. DOI: 10.1086/427222.
[35] Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005 Feb 1;40(3):477-9. DOI: 10.1086/427213.
[36] Tugume L, Rhein J, Hullsiek KH, et al. HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. J Infect Dis. 2019 Feb 23;219(6):877-883. doi: 10.1093/infdis/jiy602. DOI: 10.1093/infdis/jiy602.
[37] Loyse A, Burry J, Cohn J, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. The Lancet Infectious Diseases 2019;19:e143-e147. DOI: 10.1016/S1473-3099(18)30493-6.
[38] Wake RM, Britz E, Sriruttan C, et al. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis 2018;66:686-692. DOI: 10.1093/cid/cix872.